- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03912454
A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
BMAC is a cellular rich fraction of bone marrow aspirate that can be readily prepared at the point of care without additional processing steps to manipulate or isolate cells. In addition, BMAC contains growth factors from the peripheral blood which may promote disc healing.
Study Summary:
The study population will consist of up to 20 patients aged 18- 60 with unresolved low back pain attributable to intervertebral disc degeneration. Clinical exam will indicate the intervertebral disc as the source of pain with features such as midline pain, pain upon rising from a seated position, or positive responses to centralization maneuvers. Moderate single level lumbar disc (L1-S1) degeneration (<50% disc height) will be confirmed on MRI. Other low back pain generators must be eliminated prior to study enrollment. Subjects must meet minimum score criteria on baseline PROs (VAS>=40 and ODI>=30). Subjects that meet all of the inclusion and none of the exclusion criteria will be invited to participate in the study.
Enrolled subjects will undergo bone marrow aspiration and intradiscal injection by an experienced orthopedic spine surgeon. Subjects will be followed for 1 year to evaluate the effects of the disc injection.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Bone and Joint Clinic of Baton Rouge
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 18 to 60 years
- Symptomatic discogenic low back pain, clinically demonstrated by a loss of lumbar range of motion and pain to deep palpation over the symptomatic disc.
- MRI confirmed single level lumbar disc height loss <50% (Modified Pfirrman grade <=7).
MRI confirmed isolated lumbar disc degeneration OR
o If zygapophysial joint degeneration is present on MRI, subject must have failed intra-articular injection or medial branch block (<50% pain relief) to be eligible for enrollment. PI will have final discretion as to whether the patient's symptoms originate from a single disc.
- Patient must have completed at least 3 months conservative treatment. Conservative treatment may include NSAIDs or Acetaminophen when medically appropriate and physiotherapy, chiropractic care, or a guided home exercise program.
- BMI < 40
- Back pain greater than leg pain with back pain rating on a 100 mm visual analog scale (VAS) >= 40 mm
- Pain Catastrophizing Scale <= 30
Exclusion Criteria:
- Prior fusion at the level to be treated
- >2 levels requiring intervention
- Non discogenic source of back pain
- Intradural disc herniation
- Full thickness annular tear at the index level.
- Lumbar spine surgery within the past 6 months.
- Pregnant or breastfeeding.
- Known allergy or sensitivity to heparin or citrate (used for processing BMAC)
- Coagulopathy preventing spinal injection
- Active infection
- Malignancy within past 5 years other than basal cell or squamous cell skin cancer.
- Severe uncontrolled medical condition
- Other significant pain generator that may affect the subject's answers to PRO questionnaires.
- Current Tobacco use
- Pending litigation involving subject's back pain
- Incarcerated at the time of study enrollment
- Inability to give informed consent for study participation for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BMAC Injection
|
Subjects will undergo bone marrow aspiration from the iliac crest.
Bone marrow will be concentrated and injected into the symptomatic lumbar disc.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visual Analog Scale (VAS) Pain Score
Time Frame: 1 day (Pre-injection) to 12 months post-injection
|
The severity of back and leg pain will be evaluated using a 100 mm visual analog scale (VAS) where a higher number indicates greater pain.
|
1 day (Pre-injection) to 12 months post-injection
|
Change in Oswestry Disability Index
Time Frame: 1 day (Pre-injection) to 12 months post-injection
|
The Oswestry Disability Index (ODI) is the most commonly used patient reported outcome measure in patients with low back pain.
The ODI score ranges from 0% to 100%.
A higher score corresponds to a greater disability.
|
1 day (Pre-injection) to 12 months post-injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BMAC injection survival
Time Frame: 12 months post-injection
|
The number of subjects who do not proceed to surgery for their discogenic back pain and answer YES to " Are you satisfied with the outcome of this injection?
OR NO to "Are you seeking any additional treatments for your discogenic back pain at this time?"
|
12 months post-injection
|
MRI evaluation of the degenerative disc
Time Frame: 1 day (Pre-injection) and 12 months post-injection
|
A modified Pfirrman grade will be assigned and used to assess changes in the disc pre-injection to 1 year post - injection
|
1 day (Pre-injection) and 12 months post-injection
|
CFU-F Analysis
Time Frame: 1 Day of Injection
|
Cell viability testing and CFU-F assay will be conducted on an aliquot from each subject's BMAC.
Number of CFU-F from each patient will be used to correlate with patient reported outcomes.
|
1 Day of Injection
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BMAC1601
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
Clinical Trials on Autologous Bone Marrow Aspirate Concentrate (BMAC) Injection
-
Rush University Medical CenterRecruitingOsteoarthritis of the KneeUnited States
-
Massachusetts General HospitalRecruitingAcetabular Labrum Tear | Femoro Acetabular Impingement | Chondral Defect | Bone Marrow Aspirate ConcentrateUnited States
-
CELL Technologies Inc.Not yet recruitingMusculoskeletal Diseases | Knee OsteoarthritisCanada
-
Hospital for Special Surgery, New YorkEmory University; Arthritis FoundationNot yet recruitingAnterior Cruciate Ligament Injuries | Bone Marrow Aspirate Concentrate | ACL Injury | Post-Traumatic Osteoarthritis of KneeUnited States
-
NYU Langone HealthActive, not recruitingLumbar Degenerative Disc DiseaseUnited States
-
Rush University Medical CenterJoint Restoration FoundationCompletedCartilage InjuryUnited States
-
Mayo ClinicCompletedBilateral Primary Osteoarthritis of KneeUnited States
-
CAPRI ClinicAlberta Bone and Joint Health InstituteWithdrawnOsteoarthritis, Knee | Osteoarthritis, HipCanada
-
Cairo UniversityRecruitingDental Implantation | Implant Site ReactionEgypt
-
University of California, San DiegoRecruitingOsteo Arthritis KneeUnited States